Relapse after transplant for malignant lymphomas remains the main cause of treatment failure. Most conditioning regimens contain total body irradiation (TBI). We investigated the toxicity and efficacy of an intensified chemotherapy conditioning regimen without TBI in patients with relapsed or high-risk malignant lymphoma who had received prior radiation therapy and were therefore not eligible for TBI. Twenty patients with a median age of 38 (18-56) and relapsed or highrisk malignant non-Hodgkin's lymphoma (NHL, n = 16) or Hodgkin's disease (HD, n = 4) underwent high-dose chemotherapy consisting of busulfan (16 mg/kg), cyclophosphamide (120 mg/kg) and etoposide 30 mg/kg (n = 8) or 45 mg/kg (n = 12) followed by peripheral stem cell support (n = 14), autologous bone marrow (n = 3), allogeneic (n = 2) or syngeneic (n = 1) transplantation. All but two had chemosensitive disease before high-dose chemotherapy. The main toxicity -according to the Bearman score -was mucositis II in 18 (90%) patients; five patients (25%) suffered a grade I hepatic toxicity. GI toxicity I occurred in three (15%) and renal toxicity I in two patients (10%). Sixty percent of the patients developed transient dermatitis with erythema and three of them (15%) had skin desquamation; one patient experienced asymptomatic pancreatitis. Toxicity was slightly higher in patients treated with 45 mg/kg etoposide. One patient (5%) died of treatment-related venoocclusive disease. After a median follow-up of 50 months (24-84) the disease-free and overall survival were 50% and 55%. One of the nine relapsing patients developed secondary AML 18 months after transplant. High-dose busulfan, cyclophosphamide and etoposide is an effective regimen resulting in long-term disease-free survival in 50% of patients with relapsed malignant lymphoma and prior radiation therapy. The toxicity is moderate with a low treatment-related mortality (5%). Keywords: malignant lymphoma; high-dose chemotherapy; etoposide; busulfan; cyclophosphamide. High-dose chemotherapy and/or radiotherapy with peripheral blood stem cell support is increasingly used in patients with high-risk or relapsed malignant non-Hodgkin's lymphoma.
High-dose chemotherapy and/or radiotherapy with peripheral blood stem cell support is increasingly used in patients with high-risk or relapsed malignant non-Hodgkin's lymphoma. [1] [2] [3] Recently, a randomized trial confirmed the superiority of high-dose chemotherapy followed by autologous bone marrow transplantation over standard salvage therapy for relapsing chemosensitive non-Hodgkin's lymphoma. 4 Total body irradiation (TBI) is part of many frequently used conditioning regimens. The most frequent single cause of treatment failure has been relapse. In an attempt to decrease the relapse rate, etoposide was added to the TBI/cyclophosphamide regimen because of its known activity against lymphoma. [5] [6] [7] However, patients with prior dose-limiting radiation therapy need alternative radiationfree preparative regimens. The combination of busulfan plus cyclophosphamide (Bu/Cy) has been widely used in patients with hematological malignancies. Initially, studies using busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) provided an effective alternative to TBI plus cyclophosphamide in the treatment of AML. 8 Modification of this regimen by lowering the cyclophosphamide dose to 120 mg/kg appears to be equally effective and less toxic. 9 Studies with Bu/Cy also demonstrated significant antitumor activity in patients with lymphoid malignancy [10] [11] [12] [13] butsimiliar to TBI containing therapies -treatment failure was mainly due to relapse. We therefore conducted a study to increase efficacy by adding etoposide (30 or 45 mg/kg) to high-dose busulfan, cyclophosphamide in patients with malignant lymphoma who had received prior radiotherapy and were not eligible for a TBI containing regimen. We have previously reported the efficacy of Bu/Cy/etoposide as preparative therapy in allogeneic bone marrow transplantation of patients with AML.
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Patients and methods
Patient selection
Between November 1991 and April 1995, 20 patients with non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) who had received prior dose-limiting radiotherapy received high-dose busulfan, cyclophosphamide and etoposide followed by peripheral blood stem cell support (n = 14), autologous bone marrow (n = 3) or allogeneic (n = 2)/syngeneic (n = 1) bone marrow transplantation. Inclusion criteria included prior administration of radiotherapy greater than 20 Gy to the liver or mediastinum or greater than 30 Gy as extended or involved field to other regions.
Further eligibility criteria were age less than 60 years, ECOG performance status 0 or 1, adequate cardiac and pulmonary function and creatinine of less than 2.0 mg/dl. NHL was classified according to the Kiel and the REAL classifications. 15, 16 The transplant protocol was approved by the local ethics commission and all patients gave written informed consent.
Patient characteristics
The study included 20 patients with a median age of 38 years (range 18-56) and the following histologies: highgrade lymphoma (n = 12), follicular lymphoma (n = 2), mantle cell lymphoma (n = 2) and Hodgkin's disease (n = 4). Before high-dose chemotherapy 10 patients were in complete remission (1st CR: n = 1; 2nd CR: n = 4, 3rd CR: n = 3; 4th CR: n = 1; 5th CR: n = 1), eight in partial remission (2nd PR: n = 4; 3rd PR: n = 2; 4th PR n = 2;) and two patients were transplanted in 3rd relapse. Ten patients had had stage IV disease, but none had bone marrow involvement. The median number of prior chemotherapy regimens was 2.5 (range 1-5) ( Table 1) .
Treatment regimen
A total dose of busulfan of 16 mg/kg was administered orally in four divided doses daily for 4 days (days −8 to −5). Etoposide (30 mg/kg n = 8 or 45 mg/kg n = 12) was administered on day −4 either undiluted over 6 h or split and diluted over 1 h. There was no randomization in terms of etoposide dose: 30 mg/kg was given to patients with extended prior radiotherapy, eg to liver or mediastinum. Cyclophosphamide 60 mg/kg was given intravenously over 1 h for 2 days (days −3 and −2). Phenytoin was given to prevent busulfan induced seizures until 2 days after stopping busulfan. Uroepithelial prophylaxis was achieved with hyperhydration and mesna. Bone marrow or peripheral blood stem cells were infused 24-48 h after the last cyclophosphamide administration (day 0).
Stem cell source
Patients received hematopoietic stem cells from autologous (n = 3), allogeneic (n = 2), syngeneic (n = 1) marrow or from G-CSF-mobilized peripheral blood (n = 14). The technique for PBSC harvest following G-CSF application, cryopreservation, CD34
+ cell counting and progenitor cell assay has been described elsewhere. 17 All patients received G-CSF beginning on day +1 post transplant (10 g/kg n = 16; 5 g/kg n = 4) until engraftment.
Regimen-related toxicity
Regimen-related toxicity affecting the renal, hepatic, cardiac, pulmonary, the gastrointestinal, the CNS system and mucous membranes were graded using the Bearman score. 18 The maximum score for each organ system was recorded. Skin toxicity was described as mild in cases of erythema or as more severe in cases of desquamation. Attempts were made to exclude from this evaluation toxicities due to GVHD.
Results
All patients were evaluable for toxicity and response.
Transplant-related toxicity
One patient (5%) died of causes other than malignancy before day 100 after transplant. She developed severe hepatic toxicity, which fulfilled the Seattle criteria of venoocclusive disease (VOD) of the liver. 19 Before transplantation she had received radiotherapy to the abdomen, which is one of the major risk factors in developing VOD. All patients developed mucositis, 90% of them grade II that required intravenous analgesics. Skin toxicity was mild in 60% of patients with localized erythema mainly of palmar or plantar surfaces, only three (15%) experienced moderate toxicity with local desquamation. All cases of mucositis and skin toxicity resolved completely. Hepatic toxicity grade I with maximum serum bilirubin of 3.9 mg/dl was seen in six (30%), renal toxicity grade 1 in two and mild diarrhea (grade I) in three patients (15%). Patients treated with 45 mg/kg etoposide experienced a slightly higher degree of toxicity than patients treated with 30 mg/kg (Table 2) . One patient experienced asymptomatic pancreatitis. All patients developed fever, and in 16 patients no origin of fever could be detected (FUO), while in three patients blood cultures were positive for Staphyloccocus (n = 2) and Enterococcus (n = 1). Pneumonia caused fever in one patient. None of the patients developed cardiac, pulmonary or CNS toxicity.
Hematopoietic engraftment
All patients achieved a leukocyte count greater than 1.0/nl after a median of 11 days (range 9-30). Eighteen patients were evaluable for platelet engraftment: 15 patients achieved a self-sustained platelet count greater than 50/nl at a median of 30 days (range 11-178). Three patients died without achieving a sustained platelet count greater than 50/nl (days +35, +105, +658). The median reinfused CD34 
Response, relapse and survival
After a median follow-up of 50 months (range 24-84) nine patients (45%) relapsed and seven patients died because of relapse; one patient with relapse developed secondary acute myeloid leukemia and died. The overall survival and the disease-free survival are 55 and 50%, respectively ( Figures  1 and 2) . Five of 10 patients who were in complete remission before high-dose chemotherapy relapsed, and five are in continuous complete remission (CCR). One of eight patients who were in partial remission before highdose chemotherapy died of treatment-related hepatic toxicity, four experienced relapses, but four (50%) still remain in CCR. One of two patients transplanted in relapse died of early relapse and the other one remains in CCR. Relapses occurred in the 45 mg/kg (n = 6) as well as in the 30 mg/kg (n=3) etoposide group.
Discussion
Despite the proven benefit of high-dose chemotherapy in relapsing non-Hodgkin's lymphomas, there is no clear evidence of any superior high-dose regimen. Optimal regimens should be well tolerated and highly effective. TBI as part of many preparative regimens used is excluded in patients who have had prior dose-limiting radiotherapy. Due to the promising results of TBI, cyclophosphamide and etoposide as the preparative regimen in high-dose therapy of malignant lymphomas. 5, 20 we investigated the substitution of busulphan for TBI in patients with malignant lymphoma and prior dose-limiting radiotherapy. The feasibility and toxicity of high-dose busulfan, cyclophosphamide and etoposide has been mainly evaluated in allogenic bone marrow transplantation and has a high treatment-related mortality, mainly due to GVHD, aspergillosis and failure of engraftment. 21, 22 A study with Bu/Cy/etoposide (40 mg/kg) was conducted by Crilley et al 23 in 84 patients with hematologic malignancy and autologous or allogeneic bone marrow transplantation. Mucositis and skin symptoms were noted as frequent extramedullary toxicities. Toxic death because of VOD or pulmonary hemorrhage occurred in 8% of patients. Taking into account the extended prior treatment with chemotherapy and irradiation, the toxicity profile of Bu/Cy/etoposide in our study was moderate, with only one (5%) treatment-related death due to VOD. The extramedullary toxicity in terms of mucositis, skin and liver problems seems to be higher in the 45 mg/kg than in the 30 mg/kg group. However, the only toxic death due to VOD occurred in one patient treated with etoposide 30 mg/kg. The toxicity results were comparable to those seen with the busulfan/cyclophosphamide regimen which has been proven effective as the high-dose conditioning regimen in treatment of relapsed/refractory lymphomas, and has a low therapy-related mortality rate. [10] [11] [12] [13] In comparison to Bu/Cy alone, the addition of etoposide seems to increase mucositis and skin toxicity, which, however, resolved completely. Other nitrosourea-based regimens such as BEAM 24 or CBV 25, 26 reported a high non-relapse mortality of up to 33%. Twenty-three percent of patients who had received carmustin at a dose of 600 mg/m 2 died of idiopathic pneumonia syndrome. 25 Therefore, it is notable that no pulmonary toxicity was observed in our study despite prior radiation to the mediastinum. The overall survival and the disease-free survival of 55 and 50% of the Bu/Cy/etoposide regimen reflect promising antilymphoma activity. Five of 10 patients who were in complete remission before highdose chemotherapy are in continous complete remission (CCR). Four of eight patients who converted from PR to CR after HDT remain in CCR. Similiar results were reported by the TBI/Cy/etoposide regimens but with a higher regimen-related mortality of 8-17%. 7, 20, 25 However, due to the small number of patients in most studies a comparison to other TBI-or non-TBI-containing regimens such as CBV, BEAM or Bu/Cy is not appropriate since the outcome could also be influenced by the sorts of patient rather than only by the preparative regimen. One patient in our study developed secondary AML 18 months after transplant, which has been described infrequently following high-dose chemotherapy for Hodgkin's disease. 27 Because of the heavy pretreatment with chemotherapy and radiation therapy in this patient, the occurrence of secondary AML is unlikely to be related to high-dose chemotherapy alone. 28 It can be concluded that busulfan, cyclophosphamide and etoposide (30-45 mg/kg) as the high-dose preparative regimen is well tolerated, with low extramedullary toxicity and treatment-related mortality in patients with malignant lymphoma and prior radiotherapy. This regimen is also effective, resulting in long-term disease-free survival in 50% of patients, and warrants further investigations.
